No profile data available.
Kazia Therapeutics Limited (KZIA) is a healthcare company in the additional cancer treatment drugs industry, based in Sydney, Australia, with about 6 full-time employees.
It reported revenue of 2.31 million AUD for fiscal year 2024, and net income of -26.78 million AUD. Its market capitalization was $138.85 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2024; market data as of October 9, 2026.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
Kazia Therapeutics reported 2.31 million AUD in revenue for fiscal year 2024.
$138.85 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Innate Pharma S.a. (IPHA), Compass Therapeutics, Inc. (CMPX), ALX Oncology Holdings Inc. (ALXO), Inovio Pharmaceuticals, Inc. (INO).